Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
322
mi
from 43215
High Point, NC
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
322
mi
from 43215
High Point, NC
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
422
mi
from 43215
Norfolk, VA
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
422
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2
Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2
Status: Enrolling
Updated:  1/3/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
937
mi
from 43215
Fort Worth, TX
Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2
Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2
Status: Enrolling
Updated: 1/3/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Safety and Efficacy of Adding Azarga Adjunctive to Prostaglandin Therapy
Status: Enrolling
Updated:  1/4/2013
Contact Alcon Call Center
941
mi
from 43215
Fort Worth, TX
Safety and Efficacy of Adding Azarga Adjunctive to Prostaglandin Therapy
Status: Enrolling
Updated: 1/4/2013
Contact Alcon Call Center
941
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Latin America
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
Status: Enrolling
Updated:  1/4/2013
Alcon Call Center
941
mi
from 43215
Fort Worth, TX
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Latin America
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
Status: Enrolling
Updated: 1/4/2013
Alcon Call Center
941
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Status: Enrolling
Updated:  1/8/2013
Retinal Consultants of Arizona
1659
mi
from 43215
Phoenix, AZ
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Status: Enrolling
Updated: 1/8/2013
Retinal Consultants of Arizona
1659
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  1/8/2013
Retinal Consultants of Arizona
1659
mi
from 43215
Phoenix, AZ
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 1/8/2013
Retinal Consultants of Arizona
1659
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® Plus Sirolimus Versus Lucentis® Plus Placebo in Patients With Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  1/8/2013
Retinal Consultants of Arizona
1659
mi
from 43215
Phoenix, AZ
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® Plus Sirolimus Versus Lucentis® Plus Placebo in Patients With Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 1/8/2013
Retinal Consultants of Arizona
1659
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
Status: Enrolling
Updated:  1/8/2013
Ophthalmic Research Associates
644
mi
from 43215
Andover, MA
A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
Status: Enrolling
Updated: 1/8/2013
Ophthalmic Research Associates
644
mi
from 43215
Andover, MA
Click here to add this to my saved trials
Sirolimus for Advanced Age-Related Macular Degeneration
Pilot Study of the Evaluation of Intravitreal Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
Status: Enrolling
Updated:  1/9/2013
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Sirolimus for Advanced Age-Related Macular Degeneration
Pilot Study of the Evaluation of Intravitreal Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
Status: Enrolling
Updated: 1/9/2013
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
1982
mi
from 43215
Los Angeles, CA
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
940
mi
from 43215
Atlantis, FL
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
940
mi
from 43215
Atlantis, FL
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
432
mi
from 43215
Atlanta, GA
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
358
mi
from 43215
Rochester, NY
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
358
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
376
mi
from 43215
Anderson, SC
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
376
mi
from 43215
Anderson, SC
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
995
mi
from 43215
Houston, TX
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.
Status: Enrolling
Updated:  1/13/2013
Retina Macula Institute
1983
mi
from 43215
Torrance, CA
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.
Status: Enrolling
Updated: 1/13/2013
Retina Macula Institute
1983
mi
from 43215
Torrance, CA
Click here to add this to my saved trials
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated:  1/16/2013
Novartis Investigative Site
1660
mi
from 43215
Phoenix, AZ
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated: 1/16/2013
Novartis Investigative Site
1660
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated:  1/16/2013
Novartis Investigative Site
993
mi
from 43215
Miami, FL
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated: 1/16/2013
Novartis Investigative Site
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated:  1/16/2013
Novartis Investigative site
643
mi
from 43215
Boston, MA
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated: 1/16/2013
Novartis Investigative site
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated:  1/16/2013
Novartis Investigative Site
98
mi
from 43215
Cincinatti, OH
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated: 1/16/2013
Novartis Investigative Site
98
mi
from 43215
Cincinatti, OH
Click here to add this to my saved trials
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated:  1/16/2013
UC San Diego, Hamilton Glaucoma Center, Department of Ophthalmology
1953
mi
from 43215
La Jolla, CA
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated: 1/16/2013
UC San Diego, Hamilton Glaucoma Center, Department of Ophthalmology
1953
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated:  1/16/2013
USC, Doheny Eye Institute
1972
mi
from 43215
Los Angeles, CA
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated: 1/16/2013
USC, Doheny Eye Institute
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated:  1/16/2013
UC Davis, Medical Center, Department of Ophthalmology & Vision Science
2043
mi
from 43215
Sacramento, CA
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated: 1/16/2013
UC Davis, Medical Center, Department of Ophthalmology & Vision Science
2043
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Comparative Study of the Optical Biometer for Measurements of the Eye
Comparative Study of the Optical Biometer for the Measurements of Axial Length, Anterior Chamber Depth, Keratometry, Corneal Cylinder Axis, Corneal Thickness, White-to-White Distance, and Pupil Diameter
Status: Enrolling
Updated:  1/16/2013
Physicians Protocol
321
mi
from 43215
Greensboro, NC
Comparative Study of the Optical Biometer for Measurements of the Eye
Comparative Study of the Optical Biometer for the Measurements of Axial Length, Anterior Chamber Depth, Keratometry, Corneal Cylinder Axis, Corneal Thickness, White-to-White Distance, and Pupil Diameter
Status: Enrolling
Updated: 1/16/2013
Physicians Protocol
321
mi
from 43215
Greensboro, NC
Click here to add this to my saved trials
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Enrolling
Updated:  1/18/2013
Eye Care Center, Southern Caalifornia College of Optometry
1960
mi
from 43215
Fullerton, CA
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Enrolling
Updated: 1/18/2013
Eye Care Center, Southern Caalifornia College of Optometry
1960
mi
from 43215
Fullerton, CA
Click here to add this to my saved trials
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Enrolling
Updated:  1/18/2013
Eye Car Center, Southern California college of Optometry
1960
mi
from 43215
Fullerton, CA
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Enrolling
Updated: 1/18/2013
Eye Car Center, Southern California college of Optometry
1960
mi
from 43215
Fullerton, CA
Click here to add this to my saved trials
Optical Coherence Tomography in Multiple Sclerosis Patients
Optical Coherence Tomography in Multiple Sclerosis Patients
Status: Enrolling
Updated:  1/19/2013
Cole Eye Institute
138
mi
from 43215
Cleveland, OH
Optical Coherence Tomography in Multiple Sclerosis Patients
Optical Coherence Tomography in Multiple Sclerosis Patients
Status: Enrolling
Updated: 1/19/2013
Cole Eye Institute
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Retina Associates SW
1641
mi
from 43215
Tucson, AZ
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Retina Associates SW
1641
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
California Retinal Consultants
1980
mi
from 43215
Bakersfield, CA
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
California Retinal Consultants
1980
mi
from 43215
Bakersfield, CA
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Retina-Vitreous Associates
1979
mi
from 43215
Beverly Hilss, CA
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Retina-Vitreous Associates
1979
mi
from 43215
Beverly Hilss, CA
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Colorado Retina
1174
mi
from 43215
Golden, CO
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Colorado Retina
1174
mi
from 43215
Golden, CO
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Florida Eye Microsurgical Institute
943
mi
from 43215
Boynton Beach, FL
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Florida Eye Microsurgical Institute
943
mi
from 43215
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Retina Health Center
928
mi
from 43215
Fort Myers, FL
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Retina Health Center
928
mi
from 43215
Fort Myers, FL
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Midwest Eye Institute
166
mi
from 43215
Indianapolis, IN
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Midwest Eye Institute
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Elman Retina
339
mi
from 43215
Baltimore, MD
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Elman Retina
339
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Cumberland Valley Retina Consultants
282
mi
from 43215
Hagerstown, MD
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Cumberland Valley Retina Consultants
282
mi
from 43215
Hagerstown, MD
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Ophthalmic Consultants of Boston
643
mi
from 43215
Boston, MA
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Ophthalmic Consultants of Boston
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Vision Research Foundation
242
mi
from 43215
Grand Rapids, MI
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Vision Research Foundation
242
mi
from 43215
Grand Rapids, MI
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Vision Research Foundation
176
mi
from 43215
Royal Oak, MI
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Vision Research Foundation
176
mi
from 43215
Royal Oak, MI
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Vision Research Foundation
356
mi
from 43215
Traverse City, MI
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Vision Research Foundation
356
mi
from 43215
Traverse City, MI
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Total Practice Management
453
mi
from 43215
New Brunswick, NJ
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Total Practice Management
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Macula Care
1760
mi
from 43215
New York, NY
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Macula Care
1760
mi
from 43215
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Retina Associates of Cleveland
127
mi
from 43215
Cleveland, OH
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Retina Associates of Cleveland
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
PA Retina
322
mi
from 43215
Camp Hill, PA
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
PA Retina
322
mi
from 43215
Camp Hill, PA
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
TN Retina
332
mi
from 43215
Nashville, TN
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
TN Retina
332
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Medical Center Ophthalmology Associates
1138
mi
from 43215
San Antonio, TX
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Medical Center Ophthalmology Associates
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
University of Wisconsin
394
mi
from 43215
Madison, WI
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
University of Wisconsin
394
mi
from 43215
Madison, WI
Click here to add this to my saved trials